⚛️ Angelini Ventures co-leads €84M Series B for NUCLIDIUM's copper-based radiopharmaceutical platform

Angelini Ventures, the corporate venture arm of Angelini Industries, has co-led a €84M Series B round in NUCLIDIUM, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform.

“This investment reflects our strong conviction in the future of precision medicine and our belief in NUCLIDIUM’s potential to scale as a next-generation company. The team also brings deep radiopharmaceutical expertise and a proven track record of building high-value companies in this space.”

— Regina Hodits, Managing Director at Angelini Ventures

🔗 Read More

‍

🚀 Solence secures €1.6M in funding to tackle PCOS using AI-powered treatments

Clara Stephenson, a former Ernst & Young lawyer who built the successful French PCOS blog Les Natives after her own experience with the condition, has raised €1.6 million in seed funding. Her startup focuses on helping women navigate Polycystic Ovary Syndrome through innovative approaches.‍

🔗 Read More

‍

📈 Cathie Wood's $305M AI bet expands into breast cancer as Tempus AI (TEM) surges

Tempus is expanding its AI-powered clinical platform, Tempus Next, into breast cancer care. The company is partnering with Mercy, one of America's largest healthcare systems, which already uses the platform for lung cancer and will now add breast cancer.‍

🔗 Read More

‍

🤖 SimBioSys wins FDA approval for AI breast cancer platform

SimBioSys received a third FDA 510(k) clearance for its TumorSight Viz platform, which will help surgeons make more informed decisions regarding care.

🔗 Read More

‍

💊 Daré Bioscience receives $6M grant installment, bringing total to $37.8M of $49M commitment for smart contraceptive device with obesity applications

Daré Bioscience received $6 million in grant funding for DARE-LARC1, a smart contraceptive device that uses programmable drug delivery technology. The preclinical system administers birth control hormones long-term without daily user effort and has potential applications in obesity and diabetes.

"This funding milestone will help advance what we believe is one of the most promising smart drug delivery technologies in development today."

— Sabrina Martucci Johnson, President & CEO of Daré Bioscience

🔗 Read More

‍

‍🤝 RadNet’s Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD

RadNet has completed its acquisition of iCAD, a global leader in AI-powered breast health solutions. The deal integrates iCAD's technology and regulatory capabilities into RadNet's DeepHealth subsidiary, advancing AI-powered screening and diagnostic solutions.

🔗 Read More

‍

✅ Bayer’s Lynkuet™ wins first global approval in UK for menopause symptom relief

Bayer has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved elinzanetant, branded as Lynkuet™ (Lynkuet® in the UK), as the first dual neurokinin-targeted therapy for treating moderate to severe vasomotor symptoms (hot flashes) linked to menopause.

“This first approval worldwide marks a significant milestone for our hormone-free treatment elinzanetant to manage some of the most disruptive menopausal symptoms,"‍

— Christine Roth, Executive Vice President, Global Product Strategy and Commercialization at Bayer

🔗 Read More

‍

💰 Numan secures $60M to scale its digital health services

UK digital health company Numan has raised $60M to expand its platform, focusing on prevention, screening, and women’s health. Revenue doubled to $90M last year, with over 650,000 patients treated across obesity, men’s health, and diagnostics.‍

🔗 Read More

‍

✨ My Expert Midwife secures £1.6M to accelerate growth and retail expansion

Led by Pembroke VCT with support from angel investors. The investment will accelerate e-commerce growth, expand retail distribution, and fund research, product innovation, and partnerships. Founded by NHS midwives in 2017, the brand has experienced rapid growth in recent years.

🔗 Read More‍

‍

Another big week! Let us know what you're working on, or who we should feature next.

‍Email us at info@womenshealthweek.com and put "Scoop Request" as the subject!